昭栄薬品 announced that it had raised its first-half ordinary profit forecast from the previous ¥300 million to ¥520 million and expects a 44.8% increase. First-half profit is now expected to reach a record high for the first time in four periods.
昭栄薬品 announced after the close on 18 September that it had raised its first-half ordinary profit forecast from the previous ¥300 million to ¥520 million. The company is now expected to exceed the ¥350 million reported in the same period of the previous year, representing a 44.8% increase in first-half profit.
The full-year ordinary profit forecast has been left unchanged at the previous estimate of ¥620 million, so this revision applies only to the first half.
The company attributed the revision to strong performance in its chemicals business. Orders by volume from major domestic customers exceeded expectations, while passing on higher selling prices amid elevated natural oil and fat prices contributed to increases in revenue and profit.
The first-half cumulative period is expected to run from April to September. Further details will depend on future earnings briefings and additional disclosures.